文献速递生殖医学

应用简化经济学评价方法评估临床实践中的不孕症治疗

Applying a simplified economic evaluation approach to evaluate infertility treatments in clinical practice.
PubMed 文献 · Hum Reprod · 2024-01-01

本文提出一个简化框架,以标准IVF完整周期创建一个活产儿的成本作为基准,评估其他不孕症治疗(包括附加干预)的成本效果。以30岁女性为例,假设累积活产率44.6%、每完整周期费用12000美元,创建一个活产儿的成本约27000美元,可作为参考阈值。

要点

  • 以标准IVF每活产儿成本约27000美元作为附加干预成本效果的参考阈值。
  • 新附加干预每活产成本超过27000美元时,投资新IVF周期可能比使用附加干预更合理。
  • 该简化框架有助于在不孕症治疗中快速、客观地评估成本效果。

核心结论

  • 以标准IVF每活产儿成本约27000美元为参考阈值,可简化评估不孕症治疗及附加干预的成本效果。

研究设计与样本

  • 本文为方法学论述,提出一种简化的经济学评价框架,未报告系统检索范围或样本量。

主要发现

  • 对30岁女性,假设累积活产率44.6%、每完整周期费用12000美元,创建一个活产儿的成本约27000美元(即支付意愿)。
  • 决策是否接受新治疗取决于每额外活产的增量成本,以每活产儿27000美元为参考阈值。
  • 该阈值可随女性年龄变化,经济视角和副作用风险等因素也可发挥作用。
  • 若新附加干预或治疗每活产成本超过27000美元,投资新IVF周期可能比花费在附加干预上更合理。

关键数值与推荐

  • 参考阈值:每活产儿约27000美元,基于30岁女性、累积活产率44.6%、每完整周期费用12000美元的假设。

临床怎么用

  • 作者提出,在临床环境中可用该简化框架快速评估不孕症治疗及附加干预的成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IVF is the backbone of infertility treatment, but due to its costs, it is not affordable for everyone. The cost of IVF is further escalated by interventions added to the routine treatment, which are claimed to boost pregnancy rates, so-called add-ons. Consequently, it is critical to offset the increased costs of an intervention against a potentially higher benefit. Here, we propose using a simplified framework considering the cost of a standard IVF procedure to create one live-born baby as a benchmark for the cost-effectiveness of other fertility treatments, add-ons inclusive. This framework is a simplified approach to a formal economic evaluation, enabling a rapid assessment of cost effectiveness in clinical settings. For a 30-year-old woman, assuming a 44.6% cumulative live birth rate and a cost of $12 000 per complete cycle, the cost to create one live-born baby would be ∼$27 000 (i.e. willingness to pay). Under this concept, the decision whether to accept or reject a new treatment depends from an economic perspective on the incremental cost per additional live birth from the new treatment/add-on, with the $27 000 per live-born baby as a reference threshold. This threshold can vary with women's age, and other factors such as the economic perspective and risk of side effects can play a role. If a new add-on or treatment costs >$27 000 per live birth, it might be more rational to invest in a new IVF cycle rather than spending on the add-on. With the increasing number of novel technologies in IVF and the lack of a rapid approach to evaluate their cost-effectiveness, this simplified framework will help with a more objective assessment of the cost-effectiveness of infertility treatments, including add-ons.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Feng Q, Li W, Callander EJ, et al. Applying a simplified economic evaluation approach to evaluate infertility treatments in clinical practice. Hum Reprod. 2024. PMID: 38148026. doi:10.1093/humrep/dead265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。